Actively Recruiting
177Lu-JH04 in Patients with FAP-Positive Tumors
Led by First Affiliated Hospital of Fujian Medical University · Updated on 2024-10-10
9
Participants Needed
1
Research Sites
53 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a pilot study to assess the dosimetry, toxicity and response of 177Lu-JH04, a new FAP-targeted radiopharmaceutical, in patients with FAP-Positive Tumors. All patients underwent 68Ga-FAPI PET/CT for selection and were successively divided into three groups of 3 people each.The three groups received successively an approximately 3.70 GBq (100 mCi), 5.55 GBq (150 mCi) and 7.40 GBq (200 mCi) of 177Lu-JH04 up to 4 cycles.
CONDITIONS
Official Title
177Lu-JH04 in Patients with FAP-Positive Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Progressive advanced metastatic tumors
- Tumors with high FAP expression confirmed on 68Ga-FAPI PET/CT
- Adequate renal, haematological, and liver function
- Eastern Cooperative Oncology Group performance status of 0-2
You will not qualify if you...
- Pregnant or lactating women
- Received other radionuclide therapy in the past 6 months
- Received chemotherapy, radiotherapy, or other anti-tumor treatments in the past 28 days
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China, 350005
Actively Recruiting
Research Team
W
Weibing Miao, MD
CONTACT
G
Guochang Wang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here